Constellation Pharmaceuticals to Participate in Two Investor Conferences
August 21, 2019 09:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Announces Second-Quarter and Six-Month 2019 Financial Results
August 07, 2019 16:05 ET
|
Constellation Pharmaceuticals , Inc.
Data presented at ASCO and EHA suggest potential disease-modifying activity of CPI-0610 across the spectrum of myelofibrosis (MF) parameters, with multiple potential pathways for approval The EZH2...
Geron Corporation Reports Second Quarter 2019 Financial Results and Recent Events
August 01, 2019 16:05 ET
|
Geron Corporation
MENLO PARK, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the second quarter ended June 30, 2019, and recent events. The Company...
Geron to Announce Second Quarter Financial Results on August 1, 2019
July 25, 2019 08:00 ET
|
Geron Corporation
MENLO PARK, Calif., July 25, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2019 financial results after the market closes on...
Geron Enhances Oncology Expertise to Advance Corporate Objectives
July 18, 2019 16:15 ET
|
Geron Corporation
MENLO PARK, Calif., July 18, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the appointments of Sharon McBain as Vice President, Global Regulatory Affairs and Lynn Bodarky...
Geron Appoints Vice President, Human Resources
June 20, 2019 16:27 ET
|
Geron Corporation
MENLO PARK, Calif., June 20, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the appointment of Shannon Odam as Vice President, Human Resources. Ms. Odam joins other...
Geron Reports Two Imetelstat Data Presentations at European Hematology Association Annual Congress
June 17, 2019 08:20 ET
|
Geron Corporation
Updated 8-week RBC-TI rate for the Phase 2 portion of IMerge increased to 42%, from 37% in December 2018Updated 24-week RBC-TI rate for the Phase 2 portion of IMerge increased to 29%, from 26% in...
Geron to Webcast KOL Event on June 25, 2019
June 10, 2019 16:45 ET
|
Geron Corporation
MENLO PARK, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the Company will webcast an event on June 25, 2019, featuring key opinion leaders (KOLs)...
Interim Data for CPI-0610 in MANIFEST Clinical Trial Showed Signals of Clinical Activity in Myelofibrosis Patients
June 03, 2019 09:00 ET
|
Constellation Pharmaceuticals , Inc.
CPI-0610 showed signals of clinical activity, both as a monotherapy and in combination with ruxolitinib, in refractory myelofibrosis (MF) patientsPatients treated with CPI-0610 exhibited improvement...
Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASCO to Discuss Interim Update of Data of CPI-0610 in MANIFEST Clinical Trial
May 23, 2019 10:28 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., May 23, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...